SM
Masouridi Levrat, Stavroula
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Azacitidine-induced remission enables allogeneic transplantation in TET2/BCOR-mutant relapsed extranodal natural killer/T-cell lymphoma : a case report | Haematologica | 2026 | 1 | 0 | |||
| Blood virome after allogeneic hematopoietic stem cell transplantation | Open forum infectious diseases | 2025 | 61 | 107 | |||
| Isolation measures during the COVID-19 pandemic in transplant units may decrease respiratory infection rates and improve non-relapse mortality | Bone marrow transplantation | 2025 | 6 | 0 | |||
| Epidemiology of hospital-acquired bloodstream infections in haemato-oncology patients in Geneva, Switzerland | Infection | 2025 | 37 | 180 | |||
| Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation | Bone marrow transplantation | 2024 | 84 | 0 | |||
| Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation : a case report | Frontiers in immunology | 2024 | 59 | 136 | |||
| Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission : results of a randomized phase III study | Haematologica | 2024 | 76 | 79 | |||
| Severe anaphylaxis after chimeric antigen receptor T-cell injection : a case report | EJHaem | 2024 | 56 | 127 | |||
| Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021 | Hematological oncology | 2024 | 86 | 0 | |||
| Impact of intermittent versus continuous infusions on central line-associated bloodstream infection risk in haemato-oncology patients : a quasi-experimental study | The Journal of hospital infection | 2024 | 59 | 274 | |||
| Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs | Swiss medical weekly | 2024 | 61 | 20 | |||
| Deuxième allogreffe (mise à jour). Recommandations de la Société francophone de greffe de moelle osseuse et de thérapie cellulaire (SFGM-TC) | Bulletin du cancer | 2024 | 57 | 0 | |||
| Pre-engraftment bacteremia after allogeneic hematopoietic cell transplantation without primary fluoroquinolone antibacterial prophylaxis | Transplant infectious disease | 2024 | 64 | 146 | |||
| Epidemiology, outcomes and risk factors for recurrence of Clostridioides difficile infections following allogeneic hematopoietic cell transplantation : a longitudinal retrospective multicenter study | Bone marrow transplantation | 2024 | 80 | 82 | |||
| NK and T cell repertoire is established early after allogeneic HSCT and is profoundly imprinted by CMV reactivation | Blood advances | 2024 | 113 | 84 | |||
| Routine infectious disease consultation prior to an allogeneic hematopoietic cell transplant | Open forum infectious diseases | 2023 | 83 | 117 | |||
| Revisiting cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients | Clinical infectious diseases | 2023 | 102 | 165 | |||
| Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption | Frontiers in oncology | 2023 | 72 | 134 | |||
| Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience : Sooner is better | EJHaem | 2023 | 68 | 100 | |||
| CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients | Open forum infectious diseases | 2023 | 139 | 102 | |||
| CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation | Leukemia & lymphoma | 2023 | 75 | 78 | |||
| Graft versus host disease (GvHD) prevention in allogeneic hematopoietic stem cell transplantation: T cell depletion strategies to reduce GvHD risk while preserving graft versus tumor (GvT) effect | 2023 | 133 | 4 | ||||
| Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma | Viruses | 2023 | 155 | 128 | |||
| Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients | Antimicrobial agents and chemotherapy | 2023 | 105 | 346 | |||
| Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell Transplant | Open forum infectious diseases | 2023 | 67 | 98 | |||
| Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience : 2001-2020 | EJHaem | 2023 | 89 | 132 | |||
| Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress? | Open forum infectious diseases | 2022 | 271 | 216 | |||
| Human pegivirus-1 replication influences NK cell reconstitution after allogeneic haematopoietic stem cell transplantation | Frontiers in immunology | 2022 | 117 | 98 | |||
| Atypical pulmonary phaeohyphomycosis due to Aureobasidium spp. - case report and brief literature review | Swiss medical weekly | 2022 | 184 | 83 | |||
| Rhinovirus infections among hematopoietic stem cell transplant recipients: a pre-transplant dilemma? | Viruses | 2022 | 211 | 196 | |||
| Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients | Antimicrobial agents and chemotherapy | 2022 | 105 | 289 | |||
| Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections | Mycoses | 2022 | 305 | 195 | |||
| Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT | Bone marrow transplantation | 2022 | 269 | 123 | |||
| Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation : A Retrospective Study | Transplantation and cellular therapy | 2022 | 138 | 178 | |||
| T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients | Annals of oncology | 2022 | 262 | 129 | |||
| When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients? | Mycoses | 2022 | 101 | 81 | |||
| Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation | Blood advances | 2021 | 320 | 131 | |||
| The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft | Bone marrow transplantation | 2021 | 351 | 0 | |||
| Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease | Microbiome | 2021 | 406 | 365 | |||
| Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial | Annals of hematology | 2021 | 321 | 182 | |||
| Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study | Vaccines | 2021 | 205 | 287 | |||
| Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients | Bone marrow transplantation | 2021 | 340 | 2 | |||
| Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients | Immunity, inflammation and disease | 2021 | 373 | 190 | |||
| Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year experience | Mycopathologia | 2021 | 244 | 244 | |||
| Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients | Medical mycology | 2021 | 361 | 1 | |||
| Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir | Antimicrobial agents and chemotherapy | 2021 | 250 | 428 | |||
| Real-life considerations on antifungal treatment combinations for the management of invasive mold infections after allogeneic cell transplantation | Journal of Fungi | 2021 | 189 | 148 | |||
| Successful treatment of central nervous system lymphoproliferative disorder in a kidney-pancreas and stem cell transplanted patient using intrathecal rituximab | BMJ case reports | 2021 | 243 | 1 | |||
| Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation | Leukemia | 2020 | 403 | 302 | |||
| Torque Teno Virus as a potential biomarker for complications and survival after allogeneic hematopoietic stem cell transplantation | Frontiers in Immunology | 2020 | 559 | 199 | |||
| Intracellular Pathogen in the Cerebrospinal Fluid of an Allogeneic Hematopoietic Cell Transplant Recipient With Graft-Versus-Host Disease and Brain Lesions | Clinical infectious diseases | 2020 | 274 | 0 | |||
| Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts | Biology of Blood and Marrow Transplantation | 2020 | 338 | 288 | |||
| Optimal treatment duration of pseudomonas aeruginosa infections in allogeneic hematopoietic cell transplant recipients | Open Forum Infectious Diseases | 2020 | 464 | 147 | |||
| Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study | Transplant Infectious Disease | 2020 | 406 | 2 | |||
| Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation | Frontiers in Immunology | 2019 | 358 | 163 | |||
| Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor-A multicenter analysis | American journal of transplantation | 2019 | 152 | 81 | |||
| Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis | The Journal of Infectious Diseases | 2019 | 282 | 0 | |||
| Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation | Leukemia and Lymphoma | 2018 | 545 | 2 | |||
| Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016 | Swiss Medical Weekly | 2018 | 503 | 311 | |||
| Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome | Bone Marrow Transplantation | 2018 | 457 | 0 | |||
| Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study | BMC Infectious Diseases | 2018 | 544 | 291 | |||
| Human pegivirus persistence in the human blood virome after allogeneic haematopoietic stem cell transplantation | Clinical Microbiology and Infection | 2018 | 1,397 | 613 | |||
| Torque Teno Virus Load and Acute Rejection after Orthotopic Liver Transplantation | Transplantation | 2017 | 847 | 0 | |||
| FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission | Hematological oncology | 2017 | 538 | 3 | |||
| Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index | Bone marrow transplantation | 2016 | 650 | 2 | |||
| Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants | Bone marrow transplantation | 2016 | 677 | 4 | |||
| Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation | Frontiers in Immunology | 2016 | 518 | 294 | |||
| Torque teno virus in patients undergoing allogeneic hematopoietic stem cell transplantation for hematological malignancies | Bone marrow transplantation | 2016 | 510 | 2 | |||
| Transplantation de cellules souches hématopoïétiques périphériques partiellement déplétées en lymphocytes T chez les patients avec anémie aplastique sévère : excellents résultats et incidence élevée de chimérisme mixte | 2016 | 801 | 603 | ||||
| Complete and sustained remission of spondyloarthritis after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome | Joint bone spine | 2015 | 614 | 2 | |||
| Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies | Bone marrow research | 2015 | 586 | 180 | |||
| In-Hospital Transfer Is a Risk Factor for Invasive Filamentous Fungal Infection among Hospitalized Patients with Hematological Malignancies: A Matched Case-Control Study | Infection control and hospital epidemiology | 2015 | 620 | 1 | |||
| NK Cell Functional Impairment after Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Reduced Levels of T-bet and Eomesodermin | The Journal of immunology | 2015 | 560 | 3 | |||
| Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies | Bone marrow research | 2015 | 717 | 346 | |||
| Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion | Biology of blood and marrow transplantation | 2014 | 622 | 1 |
